Gastrointestinal Cancer | Specialty

Mutations May Help Explain Sidedness Issue in Colorectal Cancer

March 6th 2017

Arturo Loaiza-Bonilla, MD, discusses the potential role of BRAF and CTNNB1 mutations in the survival difference between colorectal cancer patients with left- and right-sided tumors.

Bekaii-Saab Discusses Sequencing and Emerging Combinations in mCRC

March 4th 2017

Tanios Bekaii-Saab, MD, discusses optimal sequencing with regorafenib (Stivarga) and TAS-102 (Lonsurf) in relapsed patients with metastatic colorectal cancer and combination regimens on the rise in the setting.

Strosberg Discusses QoL Analysis and Next Steps With Lutathera in Midgut NETS

March 4th 2017

Jonathan Strosberg, MD, discusses the overall findings of the NETTER-1 trial and the quality of life analysis in patients with midgut neuroendocrine tumors.

Interventional Radiology Improving Outcomes in Liver-Metastatic CRC

March 3rd 2017

Rahmi Oklu, MD, PhD, discusses various approaches physicians use to treat patients who have CRC with liver metastases.

Researchers Have "New Attitude" About Liver Cancer, Expert Says

March 3rd 2017

Lewis R. Roberts, MB, ChB, PhD, spoke on the current state of hepatocellular carcinoma.

Immunotherapies, Stemness Inhibitors Among Advances in Gastroesophageal Cancers

March 2nd 2017

Daniel H. Ahn, DO, discusses updates in the gastric cancer landscape, biomarker developments, and agents emerging in the pipeline.

First-Line mCRC Treatment Must Encompass Individualized Approach

March 2nd 2017

Axel Grothey, MD, discusses frontline therapy and maintenance strategies for patients with metastatic colorectal cancer.

Dr. Roberts on the Prevalence of Liver Cancer

March 1st 2017

Lewis R. Roberts, MB, ChB, PhD, professor of Medicine, Mayo Clinic, discusses the prevalence of hepatocellular carcinoma (HCC).

Dr. Bekaii-Saab on Expanding Landscape in CRC

March 1st 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the expanding treatment landscape of colorectal cancer (CRC).

Dr. Ahn on Novel Biomarkers in Gastric Cancer

February 28th 2017

Daniel H. Ahn, DO, internist, Mayo Clinic, discusses the identification of novel biomarkers in gastric cancer during the 2017 State of the Science Summit on Gastrointestinal Malignancies.

Dr. Grothey on Treatment Landscape of mCRC

February 28th 2017

Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses some of the therapeutic approaches in the field of metastatic colorectal cancer (CRC).

A Master Mentor Who Nurtured a Field

February 27th 2017

Robert J. Mayer, MD, who helped the field of oncology develop while conducting groundbreaking research, was honored in the Gastrointestinal Cancer category with a 2015 Giants of Cancer Care® award, a program that OncLive developed to recognize leaders in the field.

NYU Researchers Target Tumor Cell Metabolism in Pancreatic Cancer

February 23rd 2017

Researchers at NYU Langone Medical Center are taking an approach that focuses on the unique metabolic adaptations of pancreatic cancer.

Tivantinib Fails Phase III HCC Test

February 17th 2017

Tivantinib failed to improve overall survival compared with placebo as a second-line therapy for patients with MET-overexpressing inoperable hepatocellular carcinoma in the phase III METIV-HCC study.

Gemcitabine-Free Regimen Leads to Improved Survival in Metastatic Pancreatic Cancer

February 17th 2017

Results of the randomized phase II GERCOR trial concluded that patients with metastatic pancreatic cancer saw numerically better survival rates with a gemcitabine-free regimen when compared with a conventional gemcitabine regimen.

Response Rates Improved With Platinum Added to Nab-Paclitaxel/Gemcitabine in Advanced Pancreatic Cancer

February 16th 2017

The addition of a platinum agent to standard gemcitabine and nab-paclitaxel was found to be associated with impressive response and overall survival rates in patients with stage IV pancreatic cancer.

In MPC, Gemcitabine/Nab-Paclitaxel More Cost Effective Than With FOLFIRINOX

February 16th 2017

Real-world data presented at the 2017 Gastrointestinal Cancers Symposium demonstrated that there were significantly higher costs associated with FOLFIRINOX as first-line therapy compared with the combination of nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.

Precision Medicine and the Future of Pancreatic Cancer

February 16th 2017

PEGPH20 in Advanced Pancreatic Cancer

February 16th 2017

The Potential for Immunotherapy in Pancreatic Cancer

February 16th 2017